Utility of Breath-holding Test in Systemic Sclerosis
1 other identifier
interventional
120
1 country
1
Brief Summary
This study aims to evaluate the utility of breath-holding test as a marker of pulmonary disease severity in patients with systemic sclerosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Aug 2020
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 21, 2020
CompletedFirst Posted
Study publicly available on registry
July 24, 2020
CompletedStudy Start
First participant enrolled
August 12, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 29, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2023
CompletedJune 2, 2023
May 1, 2023
6 months
July 21, 2020
May 31, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Correlation of breath-holding test with Borg Dyspnea Index
Borg Scale on a 0-10 point
Day 1 at inclusion
Secondary Outcomes (5)
Correlation of breath-holding time with 6 minute walk test (6MWT) distance
Day 1 at inclusion
Correlation of breath-holding time with oxygen saturation during 6MWT
Day 1 at inclusion
Correlation of breath-holding time with pulmonary function indices
Day 1 at inclusion
Correlation of breath-holding time with data on the echocardiography
Day 1 at inclusion
Correlation of breath-holding time with scleroderma health assessment questionnaire (SHAQ)
Day 1 at inclusion
Other Outcomes (5)
Changes of oxygen saturation during breath-holding test
Day 1 at inclusion
Changes of oxygen saturation during of 6MWT
Day 1 at inclusion
Responsiveness of breath-holding test
Month 6 at inclusion
- +2 more other outcomes
Study Arms (1)
Systemic sclerosis group
EXPERIMENTALSystemic sclerosis diagnosis according to 2013 American College of Rheumatology(ACR)/European League Against Rheumatism(EULAR) classification criteria
Interventions
1. Participants will perform the SHAQ. 2. BHT and 6MWT will be performed in the randomized way for each participant. 3. For BHT, the participants will be told to sit comfortably on a chair, and breath normally. After 1 minute, they were required to make a maximum expiration followed by a maximum inspiration and to hold the breath as long as possible at maximum inspiratory level. This procedure was repeated three times, with 5-minute intervals between the tests. 4. 6MWT will be performed according to the ATS guidelines. 5. Information on CXR, TTE, and PFT (FVC%, DLCO%) will be obtained from the medical record if the data was obtained within 3 months. If not, the tests will be performed. 6. BHT and PFT will be followed by six months after the first breath-holding test to confirm the responsiveness. 7. Additional 30 patients with systemic sclerosis will be collected to perform the test-retest reliability of BHT.
Eligibility Criteria
You may qualify if:
- A diagnosis of systemic sclerosis according to 2013 ACR/EULAR criteria
- Must understand and voluntarily sign an informed consent form including writing consent for data protection
You may not qualify if:
- The resting oxygen saturation by pulse oximetry \< 90% in room air
- Unstable angina or myocardial infarction during the previous month
- Patients considered unable to the breath-holding test or 6 minute walk test
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Seoul National University Hospital
Seoul, 03080, South Korea
Related Publications (6)
Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol. 2011 Apr;40(2):78-83. doi: 10.1007/s12016-010-8198-y.
PMID: 20143182BACKGROUNDMorelli S, Ferrante L, Sgreccia A, Eleuteri ML, Perrone C, De Marzio P, Balsano F. Pulmonary hypertension is associated with impaired exercise performance in patients with systemic sclerosis. Scand J Rheumatol. 2000;29(4):236-42. doi: 10.1080/030097400750041389.
PMID: 11028845BACKGROUNDVandecasteele E, De Pauw M, De Keyser F, Decuman S, Deschepper E, Piette Y, Brusselle G, Smith V. Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis. Int J Cardiol. 2016 Jun 1;212:265-73. doi: 10.1016/j.ijcard.2016.03.084. Epub 2016 Mar 25.
PMID: 27057932BACKGROUNDImpens AJ, Wangkaew S, Seibold JR. The 6-minute walk test in scleroderma--how measuring everything measures nothing. Rheumatology (Oxford). 2008 Oct;47 Suppl 5:v68-9. doi: 10.1093/rheumatology/ken273.
PMID: 18784152BACKGROUNDATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available.
PMID: 12091180BACKGROUNDYeo J, Kim JY, Kim MH, Park JW, Park JK, Lee EB. Utility of the breath-holding test in patients with systemic sclerosis. Rheumatology (Oxford). 2022 Oct 6;61(10):4113-4118. doi: 10.1093/rheumatology/keac020.
PMID: 35040945DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Eun Bong Lee, MD PhD
Seoul National University College of Medicine
- STUDY DIRECTOR
Jina Yeo, MD
Seoul National University College of Medicine
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
July 21, 2020
First Posted
July 24, 2020
Study Start
August 12, 2020
Primary Completion
January 29, 2021
Study Completion
May 31, 2023
Last Updated
June 2, 2023
Record last verified: 2023-05